行情

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

1.510
-0.010
-0.66%
盘前: 1.400 -0.11 -7.28% 07:41 01/22 EST
开盘
1.520
昨收
1.520
最高
1.570
最低
1.460
成交量
44.84万
成交额
--
52周最高
7.49
52周最低
0.7200
市值
4,081.31万
市盈率(TTM)
-0.2446
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SEEL 新闻

  • Selos Therapeutics Files For $13.8M Common Stock Offering
  • Benzinga.1小时前
  • 谷歌CEO皮查伊:隐私是我们工作的核心
  • 新浪科技.2小时前
  • 谷歌CEO:AI或许是目前最重要的发明 比电的意义更大
  • 新浪科技.2小时前
  • 特朗普达沃斯演讲:种一万亿棵树,我们加入
  • 新浪财经-自媒体综合.2小时前

更多

所属板块

制药
-0.31%
制药与医学研究
-0.39%

热门股票

名称
价格
涨跌幅

SEEL 简况

Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).
展开

Webull提供Seelos Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。